-
Yang Rafn posted an update 6 months ago
Discrepancies exist between international bodies for the diagnosis of impaired fasting glucose (IFG). The aim of this study was to establish the IFG characteristics and evaluate the best diagnostic IFG criteria in a high risk dysglycaemic population.
An IFG population (
= 451) was identified from a national representative cross-sectional survey using a fasting blood glucose (FBG) ranging from 5.60 to 6.99mmol/L. These participants were invited for a follow-up oral glucose tolerance test (OGTT). Both FBG results (health survey & OGTT) were evaluated in relation to different diagnostic IFG criteria (>5.6mmol/L vs. >6.1mmol/L) while comparing to the final OGTT glycemic diagnosis.
Out of the total survey population (
= 1861), 24.34% was diagnosed with IFG. Approximately 50% of the IFG’s (
= 227) attended for the OGTT. The majority of the IFG population were male with an overweight-obese status. If the FBG cut-off point of 6.1mmol/L was followed, more than a quarter of the population attending the OGTT would have had a missed dysglycaemic status.
High-risk dysglycaemic and body mass populations may establish a more accurate dysglycaemia diagnosis and outcome when following an FBG cut-off point of >5.60mmol/L for IFG.
5.60 mmol/L for IFG.
Serum lipids and glycemic dysregulation are the known characteristics of β- thalassemia major (β-TM). Here, we evaluated the association of these disorders with insulin resistance (IR), oxidative stress and serum ferritin values in patients with β-TM.
This case-control study was performed in thalassemia unite of Darab Hospital (Darab, Fars province, Iran) from December 2016 to December 2017. Forty-eight patients with β-TM and 33 healthy individuals were enrolled. see more Serum fasting blood sugar (FBS), insulin, total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL), ischemia modified albumin (IMA), and ferritin were measured. The values of HOMA-IR, LDL TG ratio, atherogenic index (AI), atherogenic index of plasma (AIP), and coronary risk index (CRI) were calculated.
The level of serum ferritin, IMA, FBS, TG, AIP, LDL TG ratio, and the prevalence of IR (HOMA-IR < 3.8) were significantly higher while TC, LDL-C, HDL-C, and AI were significantly lower in the patients compared to the control group. In patient with β-TM, serum ferritin revealed to have a positive association with serum insulin, HOMA-IR, AI, and CRI levels while serum IMA showed positive association with TG and AIP and inverse association with hypocholesterolemia. HOMA-IR had positive correlation with HDL levels.
Oxidative stress and iron overload are predictors of serum glycemic and lipid dysregulation, suggesting possible beneficial effect of antioxidants and efficient iron chelating therapy in reducing the risk of metabolic disorders in β- thalassemia.
Oxidative stress and iron overload are predictors of serum glycemic and lipid dysregulation, suggesting possible beneficial effect of antioxidants and efficient iron chelating therapy in reducing the risk of metabolic disorders in β- thalassemia.
Proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors treatment induce large reductions in low-density lipoprotein cholesterol (LDLc) and major cardiovascular events. Clinical trials might have been underpowered to test the effect of PSCK9 inhibitors treatment on myocardial infarction and stroke, two of the most relevant cardiovascular events, since all analyzed a combined endpoint.
we performed a meta-analysis, with currently available studies involving PCSK9 inhibitors and event rate adjudication, with the aim of assessing treatment effects on myocardial infarction and stroke.
We included 81,700 patients, 41,979 treated with a PSCK9 inhibitors 17,244 with evolocumab; 13,720 with bococizumab and 11,015 with alirocumab. A total of 1,319 cases of myocardial infarctions were registered in the treatment group vs. 1,608 in controls, resulting in 19.0% reduction associated with PCSK9 treatment (RR 0.81, 95% CI 0.76-0.87). Similarly, PCSK9 inhibitors treatment resulted in a 25% reduction of stroke (RR 0.75, 95% CI 0.65-0.85) when all studies were analyzed together and the statistically significant heterogeneity was not observed in the analysis restricted to end-point based clinical trials. PCSK9 inhibitors treatment had no effect on mortality (RR 0.95, 95% CI 0.86-1.04).
PCSK9 inhibitors reduce the incidence of myocardial infarction by 19% and stroke by 25%.
PCSK9 inhibitors reduce the incidence of myocardial infarction by 19% and stroke by 25%.
Although α-amylase is the choice of target to manage postprandial hyperglycemia, inhibitors of this enzyme may get absorbed into the systemic circulation and modulate proteins involved in the pathogenesis of diabetes mellitus. Hence, the present study aimed to identify α-amylase inhibitors from
via
and
and predict their role in the modulation of multiple pathways involved in diabetes mellitus.
α-amylase inhibitory activity of hydroalcoholic extract/fractions (s) and pure compounds from
was performed using
enzyme inhibitory assay. Multiple open-source databases and published literature were used to retrieve reported phytoconstituents present in
and their targets. The network was constructed between α-amylase inhibitors, modulated proteins, and expressed pathways. Further, hit molecules were also confirmed for their potency to inhibit α-amylase using
molecular docking and
enzyme inhibitory assay. The glucose uptake assay was performed to assess the effect of hydrolcoholic extract/frase inhibitors from D. repens may not be limited within the gastrointestinal tract to inhibit α-amylase but may get absorbed into the systemic circulation and modulate multiple pathways involved in the pathogenesis of diabetes mellitus to produce synergistic/additive effect.
This study proposed to compare the prevalence and risk factors for sarcopenia by EGWSOP-1 and EWGSOP-2 diagnostic criteria in Iran.
This cross-sectional study was conducted based on the data collected during the Bushehr Elderly Health (BEH) Program, stage II. Sarcopenia was defined as 3 definitions EWGSOP-1(with Iranian cut off), EWGSOP-2(with Iranian cut off), EWGSOP-2(with European cut off) definition. We evaluated the age-standardized prevalence of sarcopenia in both genders. Regression analysis was used to show the associations in the adjusted models.
Among 2426 participants, age-standardized prevalence of sarcopenia, and severe sarcopenia by EWGSOP-1 were 19.7%, and 12.9%, in men and 13.6%, and 16.7% in women, respectively. When we used EWGSOP-2 (with Iranian cut-off) criteria, these values were 10.5%, and 12.7% among men and 7.13% and 16.5% in women, respectively. The prevalence sarcopenia and severe sarcopenia by EWGSOP-2 (with European cut-off) were 12.7%, and 13.4% in men and 5.42%, and 13.7% in women, respectively.